61510 Federal Register / Vol. 71, No.
201 / Wednesday, October 18, 2006 / Notices
20044–7611, and should refer to United
States of America v. Union Pacific
Railroad Company, D.J. Ref. 90–11–2–
08568.
The Decree may be examined at the
Office of the United States Attorney,
District of Utah, 185 South State Street,
Suite 400, Salt Lake City, Utah 84111.
During the public comment period, the
Decree may also be examined on the
following Department of Justice Web
site, http://www.usdoj.gov/enrd/
Consent_Decrees.html.
A copy of the Decree may also be
obtained by mail from the consent
Decree Library, P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611 or by faxing or e-mailing a
request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$4.50 payable to the U.S. Treasury.
Robert D. Brook,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 06–8746 Filed 10–17–06; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated May 17, 2006, and
published in the Federal Register on
May 25, 2006, (71 FR 30165), Applied
Science Labs., Division of Alltech
Associates Inc., 2701 Carolean
Industrial Drive, State College,
Pennsylvania 16801, made application
by letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Tetrahydrocannabinols (7370), a basic
class of controlled substance listed in
Schedule I.
The company plans to manufacture
metabolites of Delta-9–THC to be used
as chromatographic standards. These
compounds fall under drug code 7370
Tetrahydrocannabinols).
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Applied Science Labs to manufacture
rmajette on PROD1PC67 with NOTICES1
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Applied Science Labs to
ensure that the company’s registration is
consistent with the public interest. The
VerDate Aug<31>2005 15:24 Oct 17, 2006 Jkt 211001
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: October 11, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–17291 Filed 10–17–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on May 22,
2006, Boehringer Ingelheim Chemicals
Inc., 2820 N. Normandy Drive,
Petersburg, Virginia 23805, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Dextropropoxyphene, bulk (non-
dosage forms) (9273).
Fentanyl (9801) ............................
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
PO 00000 Frm 00054 Fmt 4703 Sfmt 4703
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than December 18, 2006.
Dated: October 6, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–17276 Filed 10–17–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 22,
2006, Boehringer Ingelheim Chemical,
Inc., 2820 N. Normandy Drive,
Petersburg, Virginia 23805, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Schedule
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
I
II II.
II The company plans to import the
II listed controlled substance to bulk
II
manufacture amphetamine.
II
Any manufacturer who is presently,
II or is applying to be, registered with DEA
to manufacture such basic class of
controlled substance may file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
E:\FR\FM\18OCN1.SGM 18OCN1